midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b
![Biodexa Pharmaceuticals logo](/files/LOGO/1643918-MTP.png)
Company profile
Ticker
BDRX
Exchange
Website
CEO
Stephen Anthony Stamp
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Midatech Pharma Plc
SEC CIK
BDRX stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
17 Jun 24
EFFECT
Notice of effectiveness
17 Jun 24
6-K
Results of Annual General Meeting
13 Jun 24
F-1
Registration statement (foreign)
6 Jun 24
424B3
Prospectus supplement
29 May 24
424B3
Prospectus supplement
29 May 24
424B3
Prospectus supplement
29 May 24
424B3
Prospectus supplement
29 May 24
424B3
Prospectus supplement
29 May 24
6-K
Current report (foreign)
28 May 24
Transcripts
Latest ownership filings
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
Cavalry Fund I LP
13 Feb 24
SC 13G
Bigger Capital, LLC
12 Feb 24
SC 13G
Mercer Street Global Opportunity Fund, LLC
8 Jan 24
SC 13G
Cavalry Fund I LP
28 Dec 23
SC 13G
Ionic Ventures, LLC
6 Mar 23
SC 13G
CVI Investments, Inc.
21 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 77.17 mm |
Total shares | 28.88 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IOI Ionic Ventures | 18.04 mm | $11.36 mm |
CVI Investments | 10.83 mm | $6.88 mm |
Susquehanna International | 11.74 k | $57.16 mm |
Rhumbline Advisers | 223.00 | $1.09 mm |
UBS UBS Group AG - Registered Shares | 71.00 | $354.00 k |
Tower Research Capital | 51.00 | $254.00 k |
MS Morgan Stanley | 16.00 | $80.00 k |
Proequities | 0.00 | $0.00 |
News
Biodexa Pharmaceuticals Presents 12-Month Phase 2 Clinical Trial Results Of eRapa In Familial Adenomatous Polyposis To Be Presented At The Biennial InSIGHT 2024 Meeting
10 Jun 24
Biodexa Pharmaceuticals Highlights Phase 2 Data Results For eRapa
3 Jun 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
28 May 24
Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results
22 May 24
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
22 May 24
Press releases
Results of Annual General Meeting
13 Jun 24
Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona
10 Jun 24
Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer
3 Jun 24
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
22 May 24
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
21 May 24